Chemomab Therapeutics Ltd. (NASDAQ: CMMB) announced that results from its Phase 2 SPRING trial of nebokitug in patients with primary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE